Jacobio Announces FDA Approves IND Application To Develop KRAS G12C Inhibitor

Jacobio Announces FDA Approves IND Application To Develop KRAS G12C Inhibitor

By, Admin 4 May 2021

The clinical trials of KRAS G12C inhibitors are expected to enroll patients in the second half of 2021. Jacobio is aiming for the in-house combination therapy of KRAS G12C and SHP2 inhibitors. Inhibitors targeting KRAS G12D and KRAS G12V mutations have lead compounds. BEIJING and SHANGHAI and BOSTON, May 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced the U.S. Food and Drug Administration (FDA) has approved company's Investigational New Drug (IND) application to develop a KRAS G12C inhibitor. IND application to the National Medical Products Administration (NMPA) in China was accepted on March 17. It will be used to treat advanced solid tumors with the KRAS G12C mutation, including but not limited to non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors. Patient enrollment for clinical trials in the U.S. and China will begin in the second half of 2021.AB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to target the KRAS G12C mutation. The global incidence of the KRAS G12C mutation in patients with NSCLC, ovarian cancer, CRC and pancreatic cancer reached approximately 295,000 in 2019. To date, there has been no approved and marketed KRAS G12C inhibitor globally. JAB-21822 has best-in-class potential among KRAS G12C inhibitors. Internal pre-clinical head-to-head animal studies comparisons have shown JAB-21822 to have a superior pharmacokinetic (PK) profile and favorable tolerability as well as potential for a superior dosing profile in comparison with its competitors. KRAS is the most frequently mutated oncogene in human cancers. KRAS mutations promote a variety of fatal tumors in humans and are present in more than 90% of pancreatic cancers. There are very limited effective treatment options for patients with pancreatic cancer, evidenced by the fact that only 7.2% of patients with pancreatic cancer have a 5-year overall survival rate in China. KRAS mutations are also found in CRC (40%), NSCLC (25%), thyroid cancer, ovarian cancer, and bladder cancer. Although KRAS and its role as an oncogene was discovered as early as 30 years ago, no therapeutic agent directly targeting KRAS has been clinically approved despite decades of research. KRAS has long been considered "undruggable" for several reasons. Firstly, it is a very small-sized molecule that has a relatively smooth surface with few deep pockets for drug-binding. Secondly, because of the high picomolar affinity of KRAS towards nucleotide GTP, drugs are generally unable to reach a certain concentration to compete with GTP in binding the nucleotide binding domain to the protein. Dr. Wayne Long, Jacobio's Vice President of Chemistry said, "The strategy of the use of allosteric inhibitors is a breakthrough of this previously "undruggable" target. Jacobio has developed the highly selective KRAS G12C inhibitor JAB-21822 based on our own allosteric inhibitor platform and an "iterative chemotype evolution" approach."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!